Difference between revisions of "Team:TokyoTech/Project/Basic Parts"

(Created page with "{{TokyoTech/css/reset}} {{TokyoTech/css/main}} <!DOCTYPE html> <html> <title>Coli Sapiens</title> <meta charset="UTF-8"> <meta name="viewport" content="width=device-width, ini...")
 
 
(25 intermediate revisions by 2 users not shown)
Line 7: Line 7:
 
<meta name="viewport" content="width=device-width, initial-scale=1">
 
<meta name="viewport" content="width=device-width, initial-scale=1">
 
<link rel="stylesheet" href="main.css">
 
<link rel="stylesheet" href="main.css">
<link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Poppins">
 
 
<style>
 
<style>
body,h1,h2,h3,h4,h5 {font-family: "Poppins", sans-serif}
+
body,h1,h2,h3,h4,h5 {font-family: "Arial", sans-serif}
 
body {font-size:16px;}
 
body {font-size:16px;}
 
.w3-half img{margin-bottom:-6px;margin-top:16px;opacity:0.8;cursor:pointer}
 
.w3-half img{margin-bottom:-6px;margin-top:16px;opacity:0.8;cursor:pointer}
Line 15: Line 14:
 
</style>
 
</style>
 
<body>
 
<body>
 +
 +
<div id="loader-bg">
 +
  <div id="loader">
 +
    <div class="photo-show">
 +
    <img src="https://static.igem.org/mediawiki/2017/f/f4/T--TokyoTech--load_1.png" width="600">
 +
    <img src="https://static.igem.org/mediawiki/2017/4/43/T--TokyoTech--load_2.png" width="600">
 +
    </div>
 +
  </div>
 +
</div>
  
 
<!-- Sidebar/menu -->
 
<!-- Sidebar/menu -->
 
<nav class="w3-sidebar w3-red w3-collapse w3-top w3-large w3-padding" style="z-index:3;width:300px;font-weight:bold;" id="mySidebar"><br>
 
<nav class="w3-sidebar w3-red w3-collapse w3-top w3-large w3-padding" style="z-index:3;width:300px;font-weight:bold;" id="mySidebar"><br>
 
   <a href="javascript:void(0)" onclick="w3_close()" class="w3-button w3-hide-large w3-display-topleft" style="width:100%;font-size:20px">Close Menu</a>
 
   <a href="javascript:void(0)" onclick="w3_close()" class="w3-button w3-hide-large w3-display-topleft" style="width:100%;font-size:20px">Close Menu</a>
   <div class="w3-container" style="margin-top: 20px;margin-bottom: 25px">
+
   <div class="w3-container" style="margin-top: 20px;margin-bottom: 25px" id="wrap">
 
     <img src="https://static.igem.org/mediawiki/2017/a/a8/T--TokyoTech--logo_white_bright_10211603.png" style="width: 100%">
 
     <img src="https://static.igem.org/mediawiki/2017/a/a8/T--TokyoTech--logo_white_bright_10211603.png" style="width: 100%">
 
   </div>
 
   </div>
  
   <div style="padding-top: 15px; padding-left: 25px;">
+
   <div style="padding-top: 15px; padding-left: 25px; id="wrap">
  
 
   <div id="contents" style="z-index: 10">
 
   <div id="contents" style="z-index: 10">
Line 50: Line 58:
 
     <label for="vmcb-d"><a>Experiment</a></label>
 
     <label for="vmcb-d"><a>Experiment</a></label>
 
     <ul>
 
     <ul>
 +
 
         <li>
 
         <li>
 
         <input type="checkbox" id="vmcb-d1" />
 
         <input type="checkbox" id="vmcb-d1" />
          <label for="vmcb-d1"><a style="text-align: center;">Bacteria to <br> Human Cells</a></label>
+
        <label for="vmcb-d1"><a href="https://2017.igem.org/Team:TokyoTech/Experiment/Overview" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white" style="text-align: center;">Overview</a></label>
 +
        </li>
 +
 
 +
        <li style="padding-bottom: 10px; padding-top: 5px">
 +
        <input type="checkbox" id="vmcb-d2" />
 +
          <label for="vmcb-d2"><a style="text-align: center;">Bacteria to <br>Human Cells </a></label>
 
             <ul>
 
             <ul>
 
               <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Experiment/TraI_Assay" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">TraI Assay</a></li>
 
               <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Experiment/TraI_Assay" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">TraI Assay</a></li>
               <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Experiment/TraI_Improvement" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">TraI <br> Impovement</a></li>
+
               <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Experiment/TraI_Improvement" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">TraI Improvement <br>Assay</a></li>
               <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Experiment/TraR_Reporter_Assay" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white" >TraR Reporter <br> Assay</a></li>
+
               <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Experiment/TraR_Reporter_Assay" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white" >TraR Reporter <br>Assay</a></li>
               <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Experiment/Transcriptome_Analysis" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Transcriptome <br> Analysis</a></li>
+
               <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Experiment/Transcriptome_Analysis" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Transcriptome <br>Analysis</a></li>
              <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Experiment/C8_Toxicity" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">C8 Toxicity <br> Assay</a></li>
+
               <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Experiment/Chimeric_Transcription_Factor" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Chimeric <br> Transcription <br> Factor Assay</a></li>
               <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Experiment/Chimeric_Transcription_Factor" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Chimeric <br> Transcription <br> Factor</a></li>
+
 
             </ul>
 
             </ul>
 
       </li>
 
       </li>
       <li><input type="checkbox" id="vmcb-d2" />
+
 
     <label for="vmcb-d2"><a style="text-align: center;">Human Cells to Bacteria</a></label>
+
       <li style="padding-bottom: 3px">
 +
      <input type="checkbox" id="vmcb-d3" />
 +
     <label for="vmcb-d3"><a style="text-align: center;">Human Cells to <br>Bacteria </a></label>
 
         <ul>
 
         <ul>
 
           <li><a href="https://2017.igem.org/Team:TokyoTech/Experiment/AHK4_Assay" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">AHK4 Assay</a></li>
 
           <li><a href="https://2017.igem.org/Team:TokyoTech/Experiment/AHK4_Assay" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">AHK4 Assay</a></li>
 
           </ul>
 
           </ul>
 +
        </li>
 +
 +
        <li>
 +
        <input type="checkbox" id="vmcb-d4" />
 +
    <label for="vmcb-d4"><a href="https://2017.igem.org/Team:TokyoTech/InterLab" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white" style="text-align: center;">InterLab</a></label>
 
         </li>
 
         </li>
 
     </ul>
 
     </ul>
Line 83: Line 103:
 
     <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/HP" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Overview</a></li>
 
     <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/HP" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Overview</a></li>
 
     <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/HP/Silver" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Silver</a></li>
 
     <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/HP/Silver" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Silver</a></li>
     <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/HP/Gold_Integrated" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Integrated <br> Human Practice</a></li>
+
     <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/HP/Gold_Integrated" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Gold (Integrated)</a></li>
 +
    <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Demonstrate" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Demonstrate</a></li>
 
     <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Collaborations" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Collaborations</a></li>
 
     <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Collaborations" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Collaborations</a></li>
 
     </ul>
 
     </ul>
Line 102: Line 123:
 
   </div>
 
   </div>
 
</nav>
 
</nav>
 +
  
 
<!-- Top menu on small screens -->
 
<!-- Top menu on small screens -->
Line 115: Line 137:
 
<div class="w3-main" style="margin-left:340px;margin-right:40px; z-index: 1">
 
<div class="w3-main" style="margin-left:340px;margin-right:40px; z-index: 1">
  
   <div class="w3-container" id="contact" style="margin-top:30px; z-index: 2">
+
   <div class="w3-container" id="contact" style="margin-top:30px"><!-- ページタイトル -->
    <img src="https://static.igem.org/mediawiki/2017/2/2c/T--TokyoTech--logo10011204.jpg" alt="John" style="width:100%">
+
      <h1 class="w3-xxxlarge w3-text-red" style="padding-bottom: 10px;padding-top: 10px" align="center">Basic Parts</h2>
  </div>
+
    </div>
 +
     
 +
      <hr>
  
  <!-- Overview -->
+
      <br>
  <div class="w3-container" id="overview" style="margin-top:20px; z-index: 3">
+
    <h1 class="w3-xxxlarge w3-text-red" style="padding-bottom: 10px;padding-top: 10px"><b>Overview</b></h1>
+
    <hr style="width:50px;border:5px solid red" class="w3-round">
+
    <p style="font-family: Poppins;font-size: 16px">Gene therapy has been expected in cancer therapy for years. An interesting therapy for cancer using anaerobic bacteria as a carrier has been developed, but after the anaerobic cancer region is diminished, the bacteria cannot stay there anymore. If anti-cancer bacteria can stay in affected area, they promptly respond to cancer recurrence. Co-existence of bacteria and host cells should be quite difficult in our body or human cell culture systems, because bacteria grow so fast. It is important to control bacterial proliferation in them. So, we try to establish a new living system that human cells control the population of bacteria by engineering the both cells by creating two signaling pathways of 1) Bacteria-Mammals and 2) Bacteria-Plants. We expect that this system will lead to a new experimental approach and a new medical therapy. Moreover, we imagine about "A boundary between cellular groups and living organisms" with general public.
+
    </p>
+
  </div>
+
  
<img src="https://static.igem.org/mediawiki/2017/d/da/T--TokyoTech--ribbon_hr.png" alt="John" style="width:95%">
+
      <div id="normal_parts_header" class="container_header" style="text-align: center;">
  
 +
        <h1><span style="padding-bottom: 2em">TokyoTech 2017 iGEM Team Basic Parts</span></h1>
 +
      </div><!-- /normal_parts_header -->
  
<!-- Project -->
+
      <br>
    <div class="w3-container" id="project" style="margin-top:20px">
+
    <h1 class="w3-xxxlarge w3-text-red" style="padding-bottom: 10px;padding-top: 10px"><b>Project  </b><a href="https://2017.igem.org/Team:TokyoTech/Project"><button class="w3-button w3-red w3-padding-large w3-hover-black" style="font-size: 25px">Read More</button></a></h1>
+
    <hr style="width:50px;border:5px solid red" class="w3-round">
+
    <p style="font-family: Poppins;font-size: 16px">Gene therapy has been expected in cancer therapy for years. An interesting therapy for cancer using anaerobic bacteria as a carrier has been developed, but after the anaerobic cancer region is diminished, the bacteria cannot stay there anymore. If anti-cancer bacteria can stay in affected area, they promptly respond to cancer recurrence. Co-existence of bacteria and host cells should be quite difficult in our body or human cell culture systems, because bacteria grow so fast. It is important to control bacterial proliferation in them. So, we try to establish a new living system that human cells control the population of bacteria by engineering the both cells by creating two signaling pathways of 1) Bacteria-Mammals and 2) Bacteria-Plants. We expect that this system will lead to a new experimental approach and a new medical therapy. Moreover, we imagine about "A boundary between cellular groups and living organisms" with general public.
+
    </p>
+
  </div>
+
  
  <hr>
+
      <div id="normal_parts_contents" class="container_contents" style="padding-right: 20px">
 +
      <center>
 +
        <table border="1" class="parts_table">
 +
          <tbody>
 +
            <tr>
 +
              <th class="parts_table_name">Name</th>
 +
              <th class="parts_table_type">Type</th>
 +
              <th class="parts_table_description">Description</th>
 +
              <th class="parts_table_design">Design</th>
 +
              <th class="parts_table_length">Length(bp)</th>
 +
            </tr>
 +
            <tr>
 +
              <td><a href="http://parts.igem.org/Part:BBa_K2505000">BBa_K2505000</a></td>
 +
              <td>Transrational unit</td>
 +
              <td><span style="font-style:italic;">rbs-ahk4</span></td>
 +
              <td>Kohei Umedera</td>
 +
              <td>3197</td>
 +
            </tr>
 +
     
 +
            <tr>
 +
              <td><a href="http://parts.igem.org/Part:BBa_K2505002">BBa_K2505002</a></td>
 +
              <td>Coding</td>
 +
              <td><span style="font-style:italic;">atIPT4</span></td>
 +
              <td>Takuma Yasue</td>
 +
              <td>960</td>
 +
            </tr>
 +
            <tr>
 +
              <td><a href="http://parts.igem.org/Part:BBa_K2505003">BBa_K2505003</a></td>
 +
              <td>Transrational unit</td>
 +
              <td>IVS-IRES-<span style="font-style:italic;">log1</span></td>
 +
              <td>Hazuki Hasegawa</td>
 +
              <td>1571</td>
 +
            </tr>
 +
           
 +
            <tr>
 +
              <td><a href="http://parts.igem.org/Part:BBa_K2505006">BBa_K2505006</a></td>
 +
              <td>Regulatory</td>
 +
              <td>P<span style="font-style:italic;">cps-rbs</span>(native)</td>
 +
              <td>Takuma Yasue</td>
 +
              <td>708</td>
 +
            </tr>
 +
 +
            <tr>
 +
              <td><a href="http://parts.igem.org/Part:BBa_K2505033">BBa_K2505033</a><br>(Best Basic Part)</td>
 +
              <td>Coding</td>
 +
              <td><span style="font-style: italic">traI</span> (K34G)</td>
 +
              <td>Kazunori Motai</td>
 +
              <td>639</td>
 +
            </tr>
 +
            <tr>
 +
              <td><a href="http://parts.igem.org/Part:BBa_K2505034">BBa_K2505034</a></td>
 +
              <td>Coding</td>
 +
              <td><span style="font-style: italic">traI</span> (Q63G)</td>
 +
              <td>Kazunori Motai</td>
 +
              <td>639</td>
 +
            </tr>
 +
            <tr>
 +
              <td><a href="http://parts.igem.org/Part:BBa_K2505035">BBa_K2505035</a></td>
 +
              <td>Coding</td>
 +
              <td><span style="font-style: italic">traI</span> (K34G, Q63G)</td>
 +
              <td>Kazunori Motai</td>
 +
              <td>639</td>
 +
            </tr>
  
  <!-- Modeling -->
+
          </tbody>
    <div class="w3-container" id="modeling" style="margin-top:20px">
+
        </table>
    <h1 class="w3-xxxlarge w3-text-red" style="padding-bottom: 10px;padding-top: 10px"><b>Modeling  </b><a href="https://2017.igem.org/Team:TokyoTech/Modeling"><button class="w3-button w3-red w3-padding-large w3-hover-black" style="font-size: 25px">Read More</button></a></h1>
+
        </center>
    <hr style="width:50px;border:5px solid red" class="w3-round">
+
<br><br>
    <p style="font-family: Poppins;font-size: 16px">Gene therapy has been expected in cancer therapy for years. An interesting therapy for cancer using anaerobic bacteria as a carrier has been developed, but after the anaerobic cancer region is diminished, the bacteria cannot stay there anymore. If anti-cancer bacteria can stay in affected area, they promptly respond to cancer recurrence. Co-existence of bacteria and host cells should be quite difficult in our body or human cell culture systems, because bacteria grow so fast. It is important to control bacterial proliferation in them. So, we try to establish a new living system that human cells control the population of bacteria by engineering the both cells by creating two signaling pathways of 1) Bacteria-Mammals and 2) Bacteria-Plants. We expect that this system will lead to a new experimental approach and a new medical therapy. Moreover, we imagine about "A boundary between cellular groups and living organisms" with general public.
+
<hr>
    </p>
+
  </div>
+
  
  <hr>
 
  
  <!-- Human Practice -->
+
<div class="w3-container" id="overview" style="margin-top:20px"><!-- この箱の中にテキストや画像をまとめる -->
  <div class="w3-container" id="hp" style="margin-top:20px">
+
     <h3 class="w3-xxxlarge w3-text-red" style="padding-bottom: 10px;padding-top: 10px"><b><span style="font-style: italic">traI</span> (K34G)</b></h3><!-- 小見出し -->
     <h1 class="w3-xxxlarge w3-text-red" style="padding-bottom: 10px;padding-top: 10px"><b>Human Practices  </b><a href="https://2017.igem.org/Team:TokyoTech/Human_Practices"><button class="w3-button w3-red w3-padding-large w3-hover-black" style="font-size: 25px">Read More</button></h1>
+
 
     <hr style="width:50px;border:5px solid red" class="w3-round">
 
     <hr style="width:50px;border:5px solid red" class="w3-round">
     <p style="font-family: Poppins;font-size: 16px">Gene therapy has been expected in cancer therapy for years. An interesting therapy for cancer using anaerobic bacteria as a carrier has been developed, but after the anaerobic cancer region is diminished, the bacteria cannot stay there anymore. If anti-cancer bacteria can stay in affected area, they promptly respond to cancer recurrence. Co-existence of bacteria and host cells should be quite difficult in our body or human cell culture systems, because bacteria grow so fast. It is important to control bacterial proliferation in them. So, we try to establish a new living system that human cells control the population of bacteria by engineering the both cells by creating two signaling pathways of 1) Bacteria-Mammals and 2) Bacteria-Plants. We expect that this system will lead to a new experimental approach and a new medical therapy. Moreover, we imagine about "A boundary between cellular groups and living organisms" with general public.
+
     <p style="font-size: 20px; text-indent:2em">Introduction</p>
 +
    <p style="font-size: 16px; text-indent:1em">
 +
In the <a href="https://2017.igem.org/Team:TokyoTech/Experiment/TraI_Assay">TraI Assay</a> page, we describe that the productivity of C8 in <span style="font-style: italic">E. coli</span> depends on the culture temperatures. However, to complete our co-culture system, the current 3OC8HSL (hereafter C8) productivity at 37℃ was not enough to transmit the AHL signal to human cells, because human cells are usually grown at 37℃. Therefore, we tried to mutate the <span style="font-style: italic">traI</span> gene and increase the productivity of C8 at 37℃ (Read <a href=https://2017.igem.org/Team:TokyoTech/Experiment/TraI_Improvement>TraI Imptovement</a> page).<br>
 
     </p>
 
     </p>
  </div>
 
  
   <hr>
+
   <br><br>
 
+
  <p style="font-size: 20px; text-indent:2em">Results</p>
  <!-- Notebook -->
+
<p style="font-size: 16px; text-indent:1em">
    <div class="w3-container" id="notebook" style="margin-top:20px">
+
When amino acid sequences of TraI and LuxI were aligned using the clustal W program (1), the E34 and E63 residues of LuxI were found to correspond to K34 and Q63 residues of TraR. According to this information, oligonucleotide primers to create TraI-K34G, TraI-Q63G, and TraI-K34G,Q63G mutants were designed. The primer sequences are shown in Fig. 1. The mutations were introduced to the pSB1C3-based traI plasmid using the inverse-PCR method, and successful introduction of the mutations were confirmed with Sanger sequencing.<br>
    <h1 class="w3-xxxlarge w3-text-red" style="padding-bottom: 10px;padding-top: 10px"><b>Notebook  </b><a href="https://2017.igem.org/Team:TokyoTech/Notebook"><button class="w3-button w3-red w3-padding-large w3-hover-black" style="font-size: 25px">Read More</button></a></h1>
+
<div class="w3-xxxlarge" style="padding-bottom: 10px;padding-top: 10px;text-align: center">
     <hr style="width:50px;border:5px solid red" class="w3-round">
+
<figure>
    <p style="font-family: Poppins;font-size: 16px">Gene therapy has been expected in cancer therapy for years. An interesting therapy for cancer using anaerobic bacteria as a carrier has been developed, but after the anaerobic cancer region is diminished, the bacteria cannot stay there anymore. If anti-cancer bacteria can stay in affected area, they promptly respond to cancer recurrence. Co-existence of bacteria and host cells should be quite difficult in our body or human cell culture systems, because bacteria grow so fast. It is important to control bacterial proliferation in them. So, we try to establish a new living system that human cells control the population of bacteria by engineering the both cells by creating two signaling pathways of 1) Bacteria-Mammals and 2) Bacteria-Plants. We expect that this system will lead to a new experimental approach and a new medical therapy. Moreover, we imagine about "A boundary between cellular groups and living organisms" with general public.
+
    <img src="https://static.igem.org/mediawiki/2017/4/43/T--TokyoTech--TraIimprove100.jpg" style="max-width:80%">
    </p>
+
    <figcaption style="font-size: 16px">Fig. 1 Sequences of the primers. Note that each primer set is divergent for inverse-PCR</figcaption>
 +
</figure>
 +
</p>
 +
     <p style="font-size: 16px; text-indent:1em">
 +
The sequences of <span style="font-style: italic">traI</span> mutants and wild-type are shown in Fig. 1. The Sender and the Reporter strains were prepared in the same way as described in the <a href="https://2017.igem.org/Team:TokyoTech/Experiment/TraI_Assay">TraI Assay</a> page.<br>
 +
   
 +
<p style="font-size: 16px; text-indent:1em">
 +
The result of C8 production using the TraI wild-type and the mutants is shown in Fig. 2. "W.T." means native <span style="font-style: italic">traI</span>.<br>
 +
The RFU value of the TraI(K34G)-expressing cells was about 3-fold higher than that of the TraI-expressing cells. <span style="font-style: italic">E. coli</span> introduced empty vector was used as Negative Control.<br>
 +
Other mutant did not show improvement of C8 production (data was not shown).<br>
 +
When these RFU values were converted to C8 concentrations using the calibration curve obtained in the reagent assay (Read <a href="https://2017.igem.org/Team:TokyoTech/Experiment/TraI_Assay">TraI Assay</a> page), they were calculated as 28 nM and 42 nM, respectively.<br>
 +
<figure>
 +
<img src="https://static.igem.org/mediawiki/2017/3/32/T--TokyoTech--TraIimprove50.jpg" style="max-width:50%">
 +
    <figcaption style="font-size: 16px">Fig. 2 Improvement of C8 production by the K34G mutant (37℃ culture)</figcaption>
 +
    </figure>
 +
</p>
 +
      </div><!-- /normal_parts_contents -->
 +
    </div><!-- /parts_2017 -->
 
   </div>
 
   </div>
  
  <hr>
 
  
  <!-- Team -->
 
    <div class="w3-container" id="team" style="margin-top:20px">
 
    <h1 class="w3-xxxlarge w3-text-red" style="padding-bottom: 10px;padding-top: 10px"><b>Team  </b><a href="https://2017.igem.org/Team:TokyoTech/Team"><button class="w3-button w3-red w3-padding-large w3-hover-black" style="font-size: 25px">Read More</button></a></h1>
 
    <hr style="width:50px;border:5px solid red" class="w3-round">
 
    <p style="font-family: Poppins;font-size: 16px">Gene therapy has been expected in cancer therapy for years. An interesting therapy for cancer using anaerobic bacteria as a carrier has been developed, but after the anaerobic cancer region is diminished, the bacteria cannot stay there anymore. If anti-cancer bacteria can stay in affected area, they promptly respond to cancer recurrence. Co-existence of bacteria and host cells should be quite difficult in our body or human cell culture systems, because bacteria grow so fast. It is important to control bacterial proliferation in them. So, we try to establish a new living system that human cells control the population of bacteria by engineering the both cells by creating two signaling pathways of 1) Bacteria-Mammals and 2) Bacteria-Plants. We expect that this system will lead to a new experimental approach and a new medical therapy. Moreover, we imagine about "A boundary between cellular groups and living organisms" with general public.
 
    </p>
 
  </div>
 
  
  <hr>
 
 
<!-- PAGE CONTENT! -->
 
 
  <div class="w3-container" id="contact" style="margin-top:75px">
 
    <img src="https://static.igem.org/mediawiki/2017/2/24/T-TokyoTech--coculture_system.jpg" alt="John" style="width:100%">
 
  </div>
 
 
 
  <!-- Sponsers -->
 
  <div class="w3-container" id="sponsers" style="margin-top:75px;">
 
    <h1 class="w3-xxxlarge w3-text-red" style="padding-top: 10px;padding-bottom: 10px"><b>Sponsers</b></h1>
 
    <hr style="width:50px;border:5px solid red" class="w3-round">
 
  </div>
 
 
  <div class="w3-row-padding">
 
    <div class="w3-col m4 w3-margin-bottom">
 
      <div class="w3-light-grey">
 
        <img src="https://static.igem.org/mediawiki/2016/4/47/Tokyo_Tech_JASSO.gif" style="width:100%">
 
        <div class="w3-container">
 
          <h3>JASSO</h3>
 
        </div>
 
      </div>
 
    </div>
 
    <div class="w3-col m4 w3-margin-bottom">
 
      <div class="w3-light-grey">
 
        <img src="http://kuramae-old.tokyo.r-cms.jp/files/user/common/p_images/head_logo.gif" style="width:100%">
 
        <div class="w3-container">
 
          <h3>Kuramae Kougyoukai</h3>
 
        </div>
 
      </div>
 
    </div>
 
    <div class="w3-col m4 w3-margin-bottom">
 
      <div class="w3-light-grey">
 
        <img src="http://www.vmcs.ucdavis.edu/idt/images/idt-logo.jpg" style="width:100%">
 
        <div class="w3-container">
 
          <h3>IDT</h3>
 
        </div>
 
      </div>
 
    </div>
 
  </div>
 
  
<!-- End page content -->
+
<div class="w3-container" id="contact" style="margin-top:20px">
 +
<p id="pageTop" style="text-align:right"><a href="#wrap"><img src="https://static.igem.org/mediawiki/2017/0/0d/T--TokyoTech--page_top_2.png" style="width:200px"></a></p>
 
</div>
 
</div>
  
 
<!-- W3.CSS Container -->
 
<!-- W3.CSS Container -->
<div class="w3-light-grey w3-container w3-padding-32" style="margin-top:75px;padding-right:58px"><p class="w3-right">Hajime Fujita:  <a href="96haji.me" title="W3.CSS" target="_blank" class="w3-hover-opacity">All Rights Reserved</a></p></div>
+
<div class="w3-light-grey w3-container w3-padding-32" style="margin-top:75px;padding-right:58px"><p class="w3-right"><a href="http://96haji.me/" title="W3.CSS" target="_blank" class="w3-hover-opacity">Hajime Fujita with W3.CSS: All Rights Reserved</a></p></div>
  
 +
<script src="http://ajax.googleapis.com/ajax/libs/jquery/1.11.1/jquery.min.js"></script>
 
<script>
 
<script>
 
// Script to open and close sidebar
 
// Script to open and close sidebar
Line 237: Line 280:
 
     document.getElementById("myOverlay").style.display = "none";
 
     document.getElementById("myOverlay").style.display = "none";
 
}
 
}
 
+
</script>
 +
<script>
 
// Modal Image Gallery
 
// Modal Image Gallery
 
function onClick(element) {
 
function onClick(element) {
Line 245: Line 289:
 
   captionText.innerHTML = element.alt;
 
   captionText.innerHTML = element.alt;
 
}
 
}
 +
$(function() {
 +
  var h = $(window).height();
 +
 +
  $('#wrap').css('display','none');
 +
  $('#loader-bg ,#loader').height(h).css('display','block');
 +
});
 +
 +
$(window).load(function () { //全ての読み込みが完了したら実行
 +
  $('#loader-bg').delay(900).fadeOut(800);
 +
  $('#loader').delay(600).fadeOut(300);
 +
  $('#wrap').css('display', 'block');
 +
});
 +
</script>
 +
<script>
 +
//■page topボタン
 +
$(function(){
 +
var topBtn=$('#pageTop');
 +
topBtn.hide();
 +
 +
//◇ボタンの表示設定
 +
$(window).scroll(function(){
 +
  if($(this).scrollTop()>80){
 +
    //---- 画面を80pxスクロールしたら、ボタンを表示する
 +
    topBtn.fadeIn();
 +
  }else{
 +
    //---- 画面が80pxより上なら、ボタンを表示しない
 +
    topBtn.fadeOut();
 +
  }
 +
});
 +
 +
// ◇ボタンをクリックしたら、スクロールして上に戻る
 +
topBtn.click(function(){
 +
  $('body,html').animate({
 +
  scrollTop: 0},500);
 +
  return false;
 +
});
 +
 +
});
 
</script>
 
</script>
  
 
</body>
 
</body>
 
</html>
 
</html>

Latest revision as of 00:07, 2 November 2017

<!DOCTYPE html> Coli Sapiens

iGEM Tokyo Tech

Basic Parts



TokyoTech 2017 iGEM Team Basic Parts


Name Type Description Design Length(bp)
BBa_K2505000 Transrational unit rbs-ahk4 Kohei Umedera 3197
BBa_K2505002 Coding atIPT4 Takuma Yasue 960
BBa_K2505003 Transrational unit IVS-IRES-log1 Hazuki Hasegawa 1571
BBa_K2505006 Regulatory Pcps-rbs(native) Takuma Yasue 708
BBa_K2505033
(Best Basic Part)
Coding traI (K34G) Kazunori Motai 639
BBa_K2505034 Coding traI (Q63G) Kazunori Motai 639
BBa_K2505035 Coding traI (K34G, Q63G) Kazunori Motai 639



traI (K34G)


Introduction

In the TraI Assay page, we describe that the productivity of C8 in E. coli depends on the culture temperatures. However, to complete our co-culture system, the current 3OC8HSL (hereafter C8) productivity at 37℃ was not enough to transmit the AHL signal to human cells, because human cells are usually grown at 37℃. Therefore, we tried to mutate the traI gene and increase the productivity of C8 at 37℃ (Read TraI Imptovement page).



Results

When amino acid sequences of TraI and LuxI were aligned using the clustal W program (1), the E34 and E63 residues of LuxI were found to correspond to K34 and Q63 residues of TraR. According to this information, oligonucleotide primers to create TraI-K34G, TraI-Q63G, and TraI-K34G,Q63G mutants were designed. The primer sequences are shown in Fig. 1. The mutations were introduced to the pSB1C3-based traI plasmid using the inverse-PCR method, and successful introduction of the mutations were confirmed with Sanger sequencing.

Fig. 1 Sequences of the primers. Note that each primer set is divergent for inverse-PCR

The sequences of traI mutants and wild-type are shown in Fig. 1. The Sender and the Reporter strains were prepared in the same way as described in the TraI Assay page.

The result of C8 production using the TraI wild-type and the mutants is shown in Fig. 2. "W.T." means native traI.
The RFU value of the TraI(K34G)-expressing cells was about 3-fold higher than that of the TraI-expressing cells. E. coli introduced empty vector was used as Negative Control.
Other mutant did not show improvement of C8 production (data was not shown).
When these RFU values were converted to C8 concentrations using the calibration curve obtained in the reagent assay (Read TraI Assay page), they were calculated as 28 nM and 42 nM, respectively.

Fig. 2 Improvement of C8 production by the K34G mutant (37℃ culture)